CD4-positive and CD8-positive T cells (DP T cells)

CD4-positive and CD8-positive T cells, commonly known as double-positive (DP) T cells, are a distinct subset of lymphocytes characterized by the simultaneous expression of both CD4 and CD8 co-receptors (Source: StatPearls, "T Cell Development"). In healthy individuals, these cells primarily represent an intermediate stage of T-cell development in the thymus, where they undergo positive and negative selection to ensure self-tolerance and functional competence (Source: NCBI, PMC4945334). While the majority of DP cells differentiate into single-positive CD4+ helper or CD8+ cytotoxic T cells, a small population persists in the peripheral blood and tissues, often increasing during chronic viral infections, autoimmune disorders, and certain malignancies (Source: Journal of Immunology Research, 2015). These cells are not traditional molecular targets but are central to the mechanism of action for many immunotherapies, including checkpoint inhibitors and T-cell engaging bispecific antibodies (Source: Nature Reviews Cancer, 2021). Therapeutic strategies involving these cells focus on modulating their activation, proliferation, or effector functions to treat diseases ranging from cancer to organ transplant rejection (Source: PubMed, 31044131).

Other names

Double-positive T cellsCD4+CD8+ T cellsDP thymocytesCD4+CD8+ lymphocytesDouble-positive thymocytes

Drugs interacting with this cell population typically function by inhibiting calcineurin to prevent T-cell activation (e.g., Cyclosporine), blocking co-stimulatory signals required for activation (e.g., Abatacept), or inhibiting immune checkpoints like PD-1 to restore effector function in exhausted cells (e.g., Pembrolizumab) (Source: StatPearls, "Immunosuppression"; Source: Nature Reviews Drug Discovery, 2018).